Cost consequences of HIV-associated lipoatrophy

AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV

Volumn 21, Issue 5, 2009, Pages 664-671

  Hornberger, J ^a,b   Rajagopalan, R ^c   Shewade, A ^a   Loutfy, M R ^d  

^a Cedar Associates LLC   (United States)

^b STANFORD UNIVERSITY   (United States)

^c ABBOTT LABORATORIES   (United States)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

Costs; Economics; HIV; Lipoatrophy

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; BIO ALCAMID; EFAVIRENZ; HYALURONIC ACID; HYDROXYAPATITE; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; POLYIMIDE; POLYLACTIC ACID; RADIESSE; SILICONE OIL; SILIKON; STAVUDINE; TENOFOVIR; UNCLASSIFIED DRUG; ZIDOVUDINE; ANTIVIRUS AGENT; BIOMATERIAL;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; BIOCOMPATIBILITY; BIODEGRADABILITY; BIOMEDICAL TECHNOLOGY ASSESSMENT; BODY FAT; CAREER; DEPRESSION; DERMIS; DRUG APPROVAL; DRUG FORMULATION; DRUG INDICATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; FACE; FOOD AND DRUG ADMINISTRATION; HEALTH CARE COST; HEALTH ECONOMICS; HEALTH INSURANCE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICAL FEE; PRIORITY JOURNAL; REIMBURSEMENT; SOCIAL ISOLATION; SYRINGE; ECONOMICS; ESTHETIC SURGERY; INTRADERMAL DRUG ADMINISTRATION; LIPODYSTROPHY;

ADMINISTRATION, CUTANEOUS; ANTIVIRAL AGENTS; BIOCOMPATIBLE MATERIALS; COSMETIC TECHNIQUES; FACE; HIV INFECTIONS; HUMANS; LIPODYSTROPHY;

EID: 70349780954     PISSN: 09540121     EISSN: 13600451     Source Type: Journal    
DOI: 10.1080/09540120802511851     Document Type: Article

References (44)

1. Ammassari, A., Antinori, A., Cozzi-Lepri, A., Trotta, M.P., Nasti, G., Ridolfo, A.L., et al. (2002). Relationship between HAART adherence and adipose tissue alterations. Journal of Acquired Immune Deficiency Syndromes, 31(Suppl. 3), S140-S144.
2. Borelli, C., Kunte, C., Weisenseel, P., Thoma-Greber, E., Korting, H.C., & Konz, B. (2005). Deep subcutaneous application of poly-L-lactic acid asa filler for facial lipoatrophy in HIV-infected patients. Skin Pharmacology and Physiology, 18(6), 273-278.
3. Boston Clinic (UK) Ltd. (2007). Retrieved October 5, 2007, from http://www.boston-clinic.co.uk/bc/public-html/pricelist/pricelist.html
4. Burgess, C.M., & Quiroga, R.M. (2005). Assessment of the safety and efficacy of poly-L-lactic acid for the treatment of HIV-associated facial lipoatrophy. Journal of the American Academy of Dermatology, 52(2), 233-239.
5. Cameron, D., da Silva, B., Arribas, J., Pulido, F., Katner, H., Wikstrom, K., et al. (2007). Significant sparing of peripheral lipoatrophy by HIV treatment with LPV/r - ZDV/3TC induction followed by LPV/r monotherapy compared with EFV - ZDV/3TC. Paper presented at the 14th Conference on Retroviruses and Opportunistic Infections. Retreived September 10, 2008, from http://www.retroconference.org/2007/Abstracts/30523.htm
6. Cattelan, A.M., Bauer, U., Trevenzoli, M., Sasset, L., Campostrini, S., Facchin, C., et al. (2006). Use of polylactic acid implantsto correct facial lipoatrophy in human immunodeficiency virus1-pos itive individuals receiving combination antiretroviral therapy. Archives of Dermatology, 142(3), 329-334.
7. Collins, E., Wagner, C., & Walmsley, S. (2000). Psychosocial impact of the lipodystrophy syndrome in HIV infection. AIDS Reader, 10(9), 546-550.
8. Denton, A.B., & Tsaparas, Y. (2007). Injectable hyaluronic acid for the correction of HIV-associated facial lipoatrophy. Archives of Otolaryngology*Head & Neck Surgery, 136(4), 563-567.
9. Echavez, M., & Horstman, W. (2005). Relationship between lipoatrophy and quality of life. AIDS Reader, 15(7), 369-375.
10. Engelhard, P. (2006). Correction optionsto lipoatrophy in HIV-infected patients. AIDS Patient Care and STDS, 20(3), 151-160.
11. Funk, E., Bressler, F.J., & Brissett, A.E. (2006). Contemporary surgical management of HIV-associated facial lipoatrophy. Archives of Otolaryngology*Head & Neck Surgery, 134(6), 1015-1022.
12. Global Drugs Direct. (2007). Retrieved October 5, 2007, from http://www.globaldrugsdirect.com/
13. Hanke, C.W., & Redbord, K.P. (2007). Safety and efficacy of poly-L-lactic acid in HIV lipoatrophy and lipoatrophy of aging. Journal of Drugs in Dermatology, 6(2), 123-128.
14. Hansen, A.B., Lindegaard, B., Obel, N., Andersen, O., Nielsen, H., & Gerstoft, J. (2006). Pronounced lipoatrophy in HIV-infected men receiving HAART for more than 6 yearscompared with the background population. HIV Medicine, 7(1), 38-45.
15. Haubrich, R., Riddler, S., DiRienzo, G., Komarow, L., Powderly, W., Garren, K., et al. (2007). Metabolic outcomes of ACTG 5142: A prospective, randomized, Phase III Trial of NRTI-, PI-, and NNRTI-sparingregimens for initial treatment of HIV-1 infection. Paper presented at the 14th Conference on Retroviruses and Opportunistic Infections. Retreived on September 10, 2008, from http://www.retroconference.org/2007/Abstracts/29065.htm
16. Hornberger, J., Holodniy, M., Robertus, K., Winnike, M., Gibson, E., & Verhulst, E. (2007). A systematic review of cost-utility analyses in HIV/AIDS: Implications for public policy. Medical Decision Making, 27(6), 789-821.
17. Jacobson, D.L., Knox, T., Spiegelman, D., Skinner, S., Gorbach, S., & Wanke, C. (2005). Prevalence of, evolution of, and risk factors for fat atrophy and fat deposition in a cohort of HIV-infected men and women. Clinical Infectious Diseases, 40(12), 1837-1845.
18. Jones, D. (2005). HIV facial lipoatrophy: Causes and treatment options. Dermatologic Surgery, 31(11 Pt 2), 1519-1529; discussion 1529.
19. Jones, D.H., Carruthers, A., Orentreich, D., Brody, H.J., Lai, M.Y., Azen, S., et al. (2004). Highly purified 1000- cSt silicone oil for treatment of human immunodeficiency virus-associated facial lipoatrophy: An open pilot trial. Dermatologic Surgery, 30(10), 1279-1286.
20. Lafaurie, M., Dolivo, M., Porcher, R., Rudant, J., Madelaine, I., & Molina, J.M. (2005). Treatment of facial lipoatrophy with intradermal injectionsof polylactic acid in HIV-infected patients. Journal of Acquired Immune Deficiency Syndromes, 38(4), 393-398.
21. Loutfy, M.R., Raboud, J.M., Antoniou, T., Kovacs, C., Shen, S., Halpenny, R., et al. (2007). Immediate versus delayed polyalkylimide gel injectionsto correct facial lipoatrophy in HIV-positive patients. AIDS, 21(9), 1147-1155.
22. Martin, A., Smith, D.E., Carr, A., Ringland, C., Amin, J., Emery, S., et al. (2004). Reversibility of lipoatrophy in HIV-infected patients2 yearsafter switching from a thymidine analogue to abacavir: The MITOX extension study. AIDS, 18(7), 1029-1036.
23. Martinez, E., Garcia-Viejo, M.A., Blanch, L., & Gatell, J.M. (2001). Lipodystrophy syndrome in patients with HIV infection: Quality of life issues. Drug Safety, 24(3), 157-166.
24. McComsey, G.A., Ward, D.J., Hessenthaler, S.M., Sension, M.G., Shalit, P., Lonergan, J.T., et al. (2004). Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: The results of the TARHEEL study. Clinical Infectious Diseases, 38(2), 263-270.
25. Mest, D.R., & Humble, G. (2006). Safety and efficacy of poly-L-lactic acid injectionsin persons with HIVassociated lipoatrophy: The US experience. Dermatologic Surgery, 32(11), 1336-1345.
26. Milinkovic, A., Lopez, S., Vidal, S., Miro, O., Fernandez, X., Amaiz, J., et al. (2005). A randomized open study comparing the effect of reducing Stavudine dose vs switching to tenofovir on mitochondrial function, metabolic parameters, and subcutaneous fat in HIV-infected patients receiving antiretroviral therapy containing Stavudine. Paper presented at the 12th conference on retroviruses and opportunistic infections. Retreived on September 10, 2008, from http://www.retrocon ference.org/2005/cd/Abstracts/25144.htm
27. Moyle, G.J., Lysakova, L., Brown, S., Sibtain, N., Healy, J., Priest, C., et al. (2004). A randomized open-label study of immediate versus delayed polylactic acid injectionsfor the cosmetic management of facial lipoatrophy in persons with HIV infection. HIV Medicine, 5(2), 82-87.
28. Moyle, G.J., Sabin, C.A., Cartledge, J., Johnson, M., Wilkins, E., Churchill, D., et al. (2006). A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AIDS, 20(16), 2043-2050.
29. PharmacyChecker.com. (2007). Retrieved October 5, 2007, from http://www.pharmacychecker.com/
30. Physician Fee Schedule. (2007). Retrieved October 5, 2007, from http://www.cms.hhs.gov/PhysicianFeeSched/.
31. Power, R., Tate, H.L., McGill, S.M., & Taylor, C. (2003). A qualitative study of the psychosocial implications of lipodystrophy syndrome on HIV positive individuals. Sexually Transmitted Infections, 79(2), 137-141.
32. Pujari, S.N., Dravid, A., Naik, E., Bhagat, S., Tash, K., Nadler, J.P., et al. (2005). Lipodystrophy and dyslipidemia among patientstaking first-line, World Health Organization-recommended highly active antiretroviral therapy regimensin Western India. Journal of Acquired Immune Deficiency Syndromes, 39(2), 199-202.
33. Rajagopalan, R., Laitinen, D., & Birgitta, D. (2008). Impact of lipoatrophy on quality of life in HIV patientsreceiving antiretroviral therapy (ART). AIDS Care, 20(10), 1197-1201.
34. Ramon, Y., Fodor, L., & Ullmann, Y. (2007). Preliminary experienceswith Bio-Alcamid in HIV facial lipoatrophy. Dermatology, 214(2), 151-154.
35. Reynolds, N.R., Neidig, J.L., Wu, A.W., Gifford, A.L., & Holmes, W.C. (2006). Balancing disfigurement and fear of disease progression: Patient perceptions of HIV body fat redistribution. AIDS Care, 18(7), 663-673.
36. Saghayam, S., Chaguturu, S.K., Kumarasamy, N., Solomon, S., Mayer, K.H., & Wanke, C. (2004). Lipoatrophy isthe predominant presentation of HIVassociated lipodystrophy in southern India. Clinical Infectious Diseases, 38(11), 1646-1647.
37. Silvers, S.L., Eviatar, J.A., Echavez, M.I., & Pappas, A.L. (2006). Prospective, open-label, 18-month trial of calcium hydroxylapatite (Radiesse) for facial soft-tissue augmentation in patients with human immunodeficiency virus-associated lipoatrophy: One-year durability. Plastic and Reconstructive Surgery, 118(Suppl. 3), 34S-45.
38. Sutinen, J. (2005). Interventionsfor managing antiretroviral therapy-associated lipoatrophy. Current Opinion Infectious Diseases, 18(1), 25-33.
39. The Lipoatrophy Resource center. (2007). Retrieved October 5, 2007, from .ast;http://thebody.com/lipo/
40. Treacy, P.J., & Goldberg, D.J. (2006). Use of a biopolymer polyalkylimide filler for facial lipodystrophy inHIV-positive patients undergoing treatment with antiretroviral drugs. Dermatologic Surgery, 32(6), 804-808.
41. Valantin, M.A., Aubron-Olivier, C., Ghosn, J., Laglenne, E., Pauchard, M., Schoen, H., et al. (2003). Polylactic acid implants(New-Fill) to correct facial lipoatrophy in HIV-infected patients: Results of the open-label study VEGA. AIDS, 17(17), 2471-2477.
42. Van Griensven, J., De Naeyer, L., Mushi, T., Ubarijoro, S., Gashumba, D., Gazille, C., et al. (2007). High prevalence of lipoatrophy among patientson stavudinecontaining first-line antiretroviral therapy regimens in Rwanda. Transactions of the Royal Society of Tropical Medicine and Hygiene, 101(8), 793-798.
43. Werschler, P., Rendon, M., Sengelmann, R., & Weinkle, S. (2006). Recognition and treatment of facial lipoatrophy with volume restoration. Retrieved June 2008, from, http://doctor.medscape.com/viewprogram/5213-pnt.
44. West Coast Skin. (2007). Retrieved October 5, 2007, from http://www.westcoastskin.com/